一个反复出现的主题：帕博利珠单抗诱发急性间质性肾炎的罕见病例。
A Recurring Theme: A Rare Case of Pembrolizumab-induced Acute Interstitial Nephritis.
作者信息
London Jonathan, Bulancea Sabrina, Shirazi Inaas, Oriuwa Victoria, Bolotova Olena, Tharayil Zubin
机构信息
Department of Internal Medicine, Long Island Community Hospital, USA.
Department of Nephrology, Long Island Community Hospital, USA.
出版信息
J Community Hosp Intern Med Perspect. 2024 Jul 2;14(4):65-67. doi: 10.55729/2000-9666.1362. eCollection 2024.
Pembrolizumab is utilized in the treatment of multiple different malignancies, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, renal cell carcinoma, endometrial cancer, and more. Pembrolizumab is an immune checkpoint inhibitor that inhibits the programmed cell death-1 (PD-1) signaling pathway. Despite its benefits in treating multiple cancers, there are many reported adverse effects of Pembrolizumab affecting various organ systems; rarely it can cause acute interstitial nephritis (AIN). We present the case of a 79-year-old male with metastatic retroperitoneal squamous cell carcinoma who was found to have recurrent acute interstitial nephritis after pembrolizumab therapy.
帕博利珠单抗被用于治疗多种不同的恶性肿瘤，包括非小细胞肺癌、头颈部鳞状细胞癌、黑色素瘤、肾细胞癌、子宫内膜癌等等。帕博利珠单抗是一种免疫检查点抑制剂，可抑制程序性细胞死亡-1（PD-1）信号通路。尽管它在治疗多种癌症方面有诸多益处，但有许多关于帕博利珠单抗的不良反应报道，其会影响各个器官系统；它很少会引起急性间质性肾炎（AIN）。我们报告了一例79岁男性转移性腹膜后鳞状细胞癌患者，该患者在接受帕博利珠单抗治疗后出现复发性急性间质性肾炎。
Zotero 插件